These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 9110396)

  • 21. Equity and the economic evaluation of healthcare.
    Sassi F; Archard L; Le Grand J
    Health Technol Assess; 2001; 5(3):1-138. PubMed ID: 11207451
    [No Abstract]   [Full Text] [Related]  

  • 22. Accounting for the missing opportunity costs in incremental cost-outcome analysis.
    Oliver A
    Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility and cost-benefit analyses: how did we get here and where are we going?
    Moayyedi P; Mason J
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):527-34. PubMed ID: 15167153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].
    Med Klin (Munich); 2000 Jan; 95(1):52-5. PubMed ID: 10668346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of patient preferences for comorbidities in cost-effectiveness analyses.
    Harris RA; Nease RF
    J Health Econ; 1997 Feb; 16(1):113-9. PubMed ID: 10167342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the decision rules of cost-effectiveness analysis.
    Johannesson M; Weinstein MC
    J Health Econ; 1993 Dec; 12(4):459-67. PubMed ID: 10131756
    [No Abstract]   [Full Text] [Related]  

  • 27. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.
    Al MJ; Feenstra TL; Hout BA
    Health Econ; 2005 Jul; 14(7):655-67. PubMed ID: 15678518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations.
    Higgins AM; Harris AH
    Crit Care Clin; 2012 Jan; 28(1):11-24, v. PubMed ID: 22123096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-benefit analyses in the health-care literature: don't judge a study by its label.
    Zarnke KB; Levine MA; O'Brien BJ
    J Clin Epidemiol; 1997 Jul; 50(7):813-22. PubMed ID: 9253393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life after stroke a comprehensive review.
    Tengs TO; Yu M; Luistro E
    Stroke; 2001 Apr; 32(4):964-72. PubMed ID: 11283398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the EQ-5D measure quality of life in schizophrenia?
    Halling Hastrup L; Nordentoft M; Hjorthøj C; Gyrd-Hansen D
    J Ment Health Policy Econ; 2011 Dec; 14(4):187-96. PubMed ID: 22345360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
    Lipman SA; Brouwer WBF; Attema AE
    Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A second opinion. Cost-utility analysis and varying preferences for health.
    Mooney G; Jan S
    Health Policy; 1997 Sep; 41(3):201-3; discussion 203-5. PubMed ID: 10170089
    [No Abstract]   [Full Text] [Related]  

  • 37. Quality-adjusted life years: origins, measurements, applications, objections.
    Schwartz S; Richardson J; Glasziou PP
    Aust J Public Health; 1993 Sep; 17(3):272-8. PubMed ID: 8286504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Controversial Issues in Economic Evaluation (II): health Outcomes of Health Care Interventions].
    Trapero-Bertran M; Brosa Riestra M; Espín Balbino J; Oliva J;
    Rev Esp Salud Publica; 2015 Apr; 89(2):125-35. PubMed ID: 26121623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-utility analysis.
    Robinson R
    BMJ; 1993 Oct; 307(6908):859-62. PubMed ID: 8401133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding DALYs (disability-adjusted life years).
    Murray CJ; Acharya AK
    J Health Econ; 1997 Dec; 16(6):703-30. PubMed ID: 10176780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.